MedNews: MediLink Therapeutics enters into a multi-target technology platform license with the immunotherapy company BioNTech (Nasdaq: BNTX) for therapies for cancer and other serious diseases
MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing conjugated drugs